Adults 18 to 60, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in the Mean Continuous Glucose Monitor (CGM) Between the Week of the Usual Care Observational Period and the Week of AIDANET At-Home.Primary· 2 weeks
This study represents a small pilot study to assess the safety and efficacy of the small-version AIDANET system and is not formally powered. Nevertheless, the randomized crossover design will allow for analysis of period effects between Group A and Group B. Comparison between these groups will be made to determine if a period effect can explain part of the benefit of the FCL system during the at-home period.
Group
Value
95% CI
Usual Care→AIDANET
-6.8
± 15.1
AIDANET→Usual Care
-2.1
± 20.7
Difference in Percent Time-in-rangeSecondary· 2 weeks
Difference in percent CGM samples in 70-180 mg/dL between the Week of the Usual Care Observational Period and the Week of AIDANET At-home. Represented as AIDANET minus Usual Care.
Group
Value
95% CI
Usual Care→AIDANET
1.55
± 4.34
AIDANET→Usual Care
2.76
± 10.6
Difference in Percent Time-below-rangeSecondary· 2 weeks
Difference in CGM percent samples \< 70mg/dL between the Week of the Usual Care Observational Period and the Week of AIDANET At-home. Represented as AIDANET minus Usual Care.
Group
Value
95% CI
Usual Care→AIDANET
0.93
± 2.10
AIDANET→Usual Care
0.06
± 0.45
Difference in Percent Time-in-tight-rangeSecondary· 2 weeks
Difference in percent CGM samples in 70-140 mg/dL between the Week of the Usual Care Observational Period and the Week of AIDANET At-home. Represented as AIDANET minus Usual Care.
Group
Value
95% CI
Usual Care→AIDANET
1.69
± 10.71
AIDANET→Usual Care
4.01
± 7.19
Sponsor's own description
A randomized 1:1 crossover trial that intends to demonstrate feasibility and safety of the Automated Insulin Delivery as Adaptive NETwork (AIDANET) system run in a new smaller network version, used in full closed loop (FCL) by adults who have been diagnosed with type 1 diabetes (T1D).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On
· Phase 1, PHASE2
· recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care
· recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
· recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1
· NA
· recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.
· NA
· recruiting
Other Marc Breton trials
Trials by the same sponsor.
NCT06017089 — The Pediatric Artificial Pancreas Automated Initialization Trial
· NA
· completed
NCT05528770 — Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop Insulin Delivery
· NA
· completed
NCT04796779 — The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
· NA
· completed
NCT03859401 — Exercise-Induced Hypoglycemia Prevention in Adults With Type 1 Diabetes Using an Artificial Pancreas
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Marc Breton
Last refreshed: 14 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06633965.